JP2003525253A - 抗ニューロトロフィン剤を用いる癌の治療方法 - Google Patents
抗ニューロトロフィン剤を用いる癌の治療方法Info
- Publication number
- JP2003525253A JP2003525253A JP2001563144A JP2001563144A JP2003525253A JP 2003525253 A JP2003525253 A JP 2003525253A JP 2001563144 A JP2001563144 A JP 2001563144A JP 2001563144 A JP2001563144 A JP 2001563144A JP 2003525253 A JP2003525253 A JP 2003525253A
- Authority
- JP
- Japan
- Prior art keywords
- neurotrophin
- antibody
- tumor
- day
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 218
- 238000000034 method Methods 0.000 title claims abstract description 75
- 201000011510 cancer Diseases 0.000 title claims abstract description 37
- 108010025020 Nerve Growth Factor Proteins 0.000 claims abstract description 177
- 102000007072 Nerve Growth Factors Human genes 0.000 claims abstract description 150
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 44
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 31
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 30
- 108090000742 Neurotrophin 3 Proteins 0.000 claims abstract description 26
- 210000002307 prostate Anatomy 0.000 claims abstract description 26
- 239000012634 fragment Substances 0.000 claims abstract description 24
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract description 23
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract description 23
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 20
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 20
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 18
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 18
- 108090000099 Neurotrophin-4 Proteins 0.000 claims abstract description 17
- 102000003683 Neurotrophin-4 Human genes 0.000 claims abstract description 14
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 12
- 241000282414 Homo sapiens Species 0.000 claims description 35
- 230000003472 neutralizing effect Effects 0.000 claims description 27
- 230000012010 growth Effects 0.000 claims description 18
- 208000023958 prostate neoplasm Diseases 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 claims description 5
- 230000035772 mutation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 description 25
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 102000015336 Nerve Growth Factor Human genes 0.000 description 22
- 229940053128 nerve growth factor Drugs 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 102000004230 Neurotrophin 3 Human genes 0.000 description 20
- 229940032018 neurotrophin 3 Drugs 0.000 description 20
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 15
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 14
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- NMMGUHANGUWNBN-OGLOGDKOSA-N cep-751 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1C[C@](OC)(CO)[C@]4(C)O1 NMMGUHANGUWNBN-OGLOGDKOSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 9
- 101150025395 trkA gene Proteins 0.000 description 9
- 101150113435 trkA1 gene Proteins 0.000 description 9
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 108090000095 Neurotrophin-6 Proteins 0.000 description 8
- 101710111575 Neurotrophin-7 Proteins 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000047459 trkC Receptor Human genes 0.000 description 5
- 108010064892 trkC Receptor Proteins 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000011717 athymic nude mouse Methods 0.000 description 4
- 230000035578 autophosphorylation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 102100033857 Neurotrophin-4 Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010082830 CEP 2563 Proteins 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- PBEVPBFDKPJIOM-HQKLUXGTSA-N Cl.Cl.C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@](OC)(COC(=O)CCNC(=O)[C@@H](N)CCCCN)[C@]4(C)O1 Chemical compound Cl.Cl.C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@](OC)(COC(=O)CCNC(=O)[C@@H](N)CCCCN)[C@]4(C)O1 PBEVPBFDKPJIOM-HQKLUXGTSA-N 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18594300P | 2000-02-29 | 2000-02-29 | |
| US60/185,943 | 2000-02-29 | ||
| US09/793,850 US6548062B2 (en) | 2000-02-29 | 2001-02-27 | Method of treating cancer with anti-neurotrophin agents |
| US09/793,850 | 2001-02-27 | ||
| PCT/US2001/006266 WO2001064247A2 (en) | 2000-02-29 | 2001-02-28 | Method of treating cancer with anti-neurotrophin agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003525253A true JP2003525253A (ja) | 2003-08-26 |
| JP2003525253A5 JP2003525253A5 (enExample) | 2008-04-10 |
Family
ID=26881613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001563144A Pending JP2003525253A (ja) | 2000-02-29 | 2001-02-28 | 抗ニューロトロフィン剤を用いる癌の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6548062B2 (enExample) |
| EP (1) | EP1261372B1 (enExample) |
| JP (1) | JP2003525253A (enExample) |
| CN (1) | CN1227033C (enExample) |
| AT (1) | ATE361100T1 (enExample) |
| AU (2) | AU2001239913B2 (enExample) |
| CA (1) | CA2401604C (enExample) |
| DE (1) | DE60128208T2 (enExample) |
| ES (1) | ES2286110T3 (enExample) |
| HK (1) | HK1049961B (enExample) |
| MX (1) | MXPA02008465A (enExample) |
| NZ (1) | NZ521165A (enExample) |
| WO (1) | WO2001064247A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504101A (ja) * | 2002-10-28 | 2006-02-02 | ビオメリュー | ｉｎｖｉｔｒｏで乳がんを診断するためのＮＧＦアッセイの方法及び治療におけるその使用 |
| JP2012067081A (ja) * | 2010-08-24 | 2012-04-05 | Okayama Univ | 疼痛の治療剤 |
| JP2015092170A (ja) * | 2008-05-21 | 2015-05-14 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） | ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用 |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
| JP3773733B2 (ja) * | 2000-01-13 | 2006-05-10 | 松下電器産業株式会社 | 陰極線管 |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| CN1684708A (zh) * | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| US20060147450A1 (en) * | 2002-10-04 | 2006-07-06 | Shelton David L | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| WO2005000194A2 (en) | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| JP4584713B2 (ja) * | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| CN101014364B (zh) * | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| PL379983A1 (pl) * | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje |
| US20050043215A1 (en) * | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| EA013614B1 (ru) * | 2003-07-15 | 2010-06-30 | Амджен Инк. | Изолированное антитело к фактору роста нервов (ngf) и способы его применения |
| ES2616337T3 (es) * | 2003-12-12 | 2017-06-12 | Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors | Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1 |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| EP3372614B1 (en) * | 2004-04-07 | 2022-06-08 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| NZ556157A (en) | 2005-01-24 | 2009-09-25 | Elan Pharma Int Ltd | Specific binding members for NGF |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| RS53661B1 (sr) | 2007-08-10 | 2015-04-30 | Regeneron Pharmaceuticals, Inc. | Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| JP2012515158A (ja) | 2009-01-12 | 2012-07-05 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| EA201190115A1 (ru) | 2009-01-24 | 2012-02-28 | ФИТОФАРМ ПиЭлСи | Лечение расстройств, опосредованных нейротрофическим фактором |
| US8435523B2 (en) * | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| CA2808577C (en) | 2010-08-19 | 2018-09-25 | Abbott Laboratories | Anti-ngf antibodies and their use |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| AU2013271564A1 (en) | 2012-06-06 | 2014-12-04 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| EP2859019B1 (en) | 2012-06-08 | 2018-02-21 | Glenmark Pharmaceuticals S.A. | Humanized anti-trka antibodies with amino acid substitutions |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| CA3093772C (en) | 2018-03-12 | 2024-04-16 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
| MX2024007088A (es) | 2021-12-16 | 2024-08-22 | Intervet Int Bv | Anticuerpos caninizados contra el ngf humano. |
| EP4514998A1 (en) | 2022-04-27 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
| US20240310383A1 (en) | 2023-03-17 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Proteomic Risk Score For Osteoarthritis (OA) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510612A (ja) * | 1994-03-18 | 1997-10-28 | ジェネンテク・インコーポレイテッド | ヒトｔｒｋ受容体および神経栄養因子インヒビター |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073264A (zh) | 1991-11-12 | 1993-06-16 | 里珍纳龙药品有限公司 | 基于组织的特定的nt-3表达与受体结合的治疗和诊断方法 |
| AU5102493A (en) | 1992-09-11 | 1994-04-12 | Cephalon, Inc. | A method for the detection and treatment of prostate disease |
| EP0753013A1 (en) * | 1994-03-29 | 1997-01-15 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Neurotrophin-6: a new member of the neurotrophin family |
-
2001
- 2001-02-27 US US09/793,850 patent/US6548062B2/en not_active Expired - Lifetime
- 2001-02-28 CA CA2401604A patent/CA2401604C/en not_active Expired - Fee Related
- 2001-02-28 CN CNB018058108A patent/CN1227033C/zh not_active Expired - Fee Related
- 2001-02-28 AU AU2001239913A patent/AU2001239913B2/en not_active Ceased
- 2001-02-28 AT AT01914537T patent/ATE361100T1/de not_active IP Right Cessation
- 2001-02-28 MX MXPA02008465A patent/MXPA02008465A/es active IP Right Grant
- 2001-02-28 AU AU3991301A patent/AU3991301A/xx active Pending
- 2001-02-28 NZ NZ521165A patent/NZ521165A/en not_active IP Right Cessation
- 2001-02-28 JP JP2001563144A patent/JP2003525253A/ja active Pending
- 2001-02-28 DE DE60128208T patent/DE60128208T2/de not_active Expired - Lifetime
- 2001-02-28 HK HK03102054.6A patent/HK1049961B/en not_active IP Right Cessation
- 2001-02-28 EP EP01914537A patent/EP1261372B1/en not_active Expired - Lifetime
- 2001-02-28 WO PCT/US2001/006266 patent/WO2001064247A2/en not_active Ceased
- 2001-02-28 ES ES01914537T patent/ES2286110T3/es not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510612A (ja) * | 1994-03-18 | 1997-10-28 | ジェネンテク・インコーポレイテッド | ヒトｔｒｋ受容体および神経栄養因子インヒビター |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504101A (ja) * | 2002-10-28 | 2006-02-02 | ビオメリュー | ｉｎｖｉｔｒｏで乳がんを診断するためのＮＧＦアッセイの方法及び治療におけるその使用 |
| JP2015092170A (ja) * | 2008-05-21 | 2015-05-14 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） | ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用 |
| JP2012067081A (ja) * | 2010-08-24 | 2012-04-05 | Okayama Univ | 疼痛の治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001239913B2 (en) | 2005-12-08 |
| HK1049961A1 (en) | 2003-06-06 |
| HK1049961B (en) | 2007-09-14 |
| ES2286110T3 (es) | 2007-12-01 |
| CA2401604A1 (en) | 2001-09-07 |
| MXPA02008465A (es) | 2003-03-10 |
| CA2401604C (en) | 2011-05-24 |
| WO2001064247A3 (en) | 2002-02-14 |
| EP1261372A2 (en) | 2002-12-04 |
| NZ521165A (en) | 2004-08-27 |
| US20010046959A1 (en) | 2001-11-29 |
| EP1261372B1 (en) | 2007-05-02 |
| CN1227033C (zh) | 2005-11-16 |
| ATE361100T1 (de) | 2007-05-15 |
| DE60128208D1 (de) | 2007-06-14 |
| CN1420785A (zh) | 2003-05-28 |
| DE60128208T2 (de) | 2008-01-10 |
| US6548062B2 (en) | 2003-04-15 |
| AU3991301A (en) | 2001-09-12 |
| WO2001064247A2 (en) | 2001-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003525253A (ja) | 抗ニューロトロフィン剤を用いる癌の治療方法 | |
| AU2001239913A1 (en) | Method of treating cancer with anti-neurotrophin agents | |
| JP2023116746A (ja) | 線維芽増殖因子受容体２に対するモノクローナル抗体 | |
| AU687346B2 (en) | A combination of anti-erbB-2 monoclonal antibodies and method of using | |
| JP4620808B2 (ja) | 突然変異上皮成長因子受容体を標的とする試薬および方法 | |
| JP2009155335A (ja) | 抗癌療法のためのマクロファージマイグレーション阻害因子アンタゴニストの使用 | |
| PT1375520E (pt) | Apoptose induzida pelo anticorpo monoclonal anti-her2 | |
| KR20050067174A (ko) | 신경성장인자 길항제 및 아편유사 진통제를 투여함에 의해통증을 치료하는 방법과 그를 함유한 조성물 | |
| EA019595B1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| TW201002346A (en) | Combination of HGF inhibitor and EGF inhibitor to treat cancer | |
| WO2004071573A2 (en) | Hypoxia induced mitogenic factor | |
| JP7495489B2 (ja) | ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質 | |
| JP2023512181A (ja) | 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ | |
| CN111848805A (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
| US11629186B2 (en) | Anti-CCL8 antibodies and uses thereof | |
| US8754031B2 (en) | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway | |
| CN115814104A (zh) | 抗体药物偶联物制剂及其用途 | |
| WO2012048667A1 (zh) | 表皮生长因子受体的外显子缺失变异体 | |
| HK40085220A (en) | Antibody drug conjugate formulation and use thereof | |
| US11198733B2 (en) | Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor | |
| HK40084158A (en) | Use of antibody-drug conjugate, and combined drug and use thereof | |
| HK40085445A (en) | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer | |
| Greene et al. | Targeted Therapy of Her2/neu Mediated Tumors | |
| HK1078590B (en) | Novel anti-igf-ir antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080220 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080430 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110312 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110705 |